İsmail AĞIRBAŞ, Ferda IŞIKÇELİK, Cansın TULUNAY KAYA

An Analysis of Cost-Effectiveness of Stents Used in the Treatment of Coronary Artery Disease

Background: There is only limited information about the cost-effectiveness of drug-eluting stents compared with bare-metal stents in Turkey.Aims: To evaluate bare-metal and drug-eluting stents used in the treatment of coronary artery disease from the perspective of the reimbursement institution with cost-effectiveness analysis.Study Design: Retrospective cost-effectiveness analysis.Methods: In our study, 329 patients diagnosed with coronary artery disease and treated with bare-metal or drug-eluting stents in the cardiology clinics of a public university hospital between January 1 and December 31, 2016 were investigated. Bare-metal and drug-eluting stents used in the treatment of coronary artery disease were evaluated retrospectively with cost-effectiveness analysis from the perspective of the reimbursement institution.Results: The cost of treatment with a bare-metal stent was 2,131.41 Turkish Liras, and the cost of treatment with a drug-eluting stent was 3,546.14 Turkish Liras; the Quality Adjusted Life Years value of treatment with a bare-metal stent was 0.8371, and the Quality Adjusted Life Years value of treatment with a drug-eluting stent was 0.8924. All these data were analyzed by decision tree. As a result of decision tree analysis, the weighted cost of treatment with a bare-metal stent was 2,340.71 Turkish Liras and weighted Quality Adjusted Life Years value was 0.8332; and the weighted cost of treatment with drug-eluting stent was 3,970.90 Turkish Liras and the weighted Quality Adjusted Life Years value of the treatment with drug-eluting stent was 0.8911. With these values, the additional cost-effectiveness ratio was calculated as 28,179.12 Turkish Liras per acquired Quality Adjusted Life Years. The additional cost-effectiveness ratio is in the first zone in the cost-effectiveness plane and below the very threshold of cost-effectiveness.Conclusion: In our study, it was concluded that drug-eluting stents are cost effective compared with bare-metal stents in the treatment of coronary artery disease. Considering the cost and effectiveness of the drug-eluting stent, it is thought that increasing reimbursement for this technology by the reimbursement agency would be beneficial for the service provider.

PDF

___

Kutay V, Ekim H, Kırali K, Güler M, Yakut C. Profile and cabg results of coronary artery patients who live around Van and regional cities. Turk Jof Thoracic and Cardio Surg 2003;11:1-4.
Jonsson E, Banta D. Management of health technologies: An international view. BMJ 1999;319:1-3.
Santerre R, Neun S. Health economics theory, insights, and industry studies. 6th ed. South Western: Cengace Learning; 2013.
GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: A systematic analysis for the global burden of disease study. Lancet 2017.
American Heart Association. Heart Disease and Stroke Statistics-2018. Update; 2018.
Tokgözoğlu L. Ulusal hastalık yükü çalışması’nın kardiyolog gözüyle değerlendirilmesi. Ulusal hastalık yükü çalışması sonuçları ve çözüm önerileri. Hacettepe University Faculty of Medicine, Ankara; 2017.
Mercanoğlu GO, Pamukçu B, Safran N, Mercanoğlu F, Fici F, Güngör M. Nebivolol prevents remodeling in a rat myocardial infarction model: an echocardiographic study. Anadolu Kardiyol Derg 2010;10:18-27.
Öncel D, Öncel G. Koroner arter stentlerinin değerlendirilmesi. Türk Radyoloji Seminerleri 2013:1:70-82.
Koplay M, Erol C. Koroner Arter Hastalığı. Türk Radyoloji Seminerleri 2013;1:57-69.
Okmen AS, Okmen E. Drug-eluting stents in multivessel coronary artery disease: Was one of the important fortresses of surgery conquered? Anadolu Kardiyol Derg 2009;9:325-30.
Tanındı A, Ekici B, Töre HF. Do pre-procedural laboratory parameters predict drug-eluting stent restenosis? Turk Kardiyol Dern Ars 2015;43:457-64.
Official Gazette No. 30175, dated 09/09/2017, Available from: http://www. resmigazete.gov.tr/eskiler/2017/09/20170909-1.htm.
Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 2015;93:118-24.
Onat A, Karakoyun S, Akbaş T, Karadeniz FÖ, Karadeniz Y, Çakır H, et al. Turkish
Adult Risk Factor survey 2014: Overall mortality and coronary disease incidence in Turkey’s geographic regions. Turk Kardiyol Dern Ars 2015;43:326-32.
Cohen DJ, Bakhai A, Shi C, Githiora L, Lavelle T, Berezin RH, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of
Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial. Circulation 2004;110:508-14.
Hill R, Bagust A, Bakhai A, Dickson R, Dündar Y, Haycox A, et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004;8:iii-iv, 1-242.
Brophy JM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care 2005;21:326-33.
Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005;366:921-9.
Lord SJ, Howard K, Allen F, Marinovich L, Burgess DC, King R, et al. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Aust 2005;183:464-71.
Shrive FM, Manns BJ, Galbraith PD, Knudtson ML, Ghali WA; APPROACH Investigators. Economic evaluation of sirolimus-eluting stents. CMAJ 2005;172:345-51.
Rinfret S, Cohen DJ, Tahami Monfared AA, Lelorier J, Mireault J, Schampaert E. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial. Am J Cardiovasc Drugs 2006;6:159-68.
Ekman M, Sjögren I, James S. Cost-effectiveness of the Taxus paclitaxel-eluting stent in the Swedish healthcare system. Scand Cardiovasc J 2006;40:17-24.
Kuukasjärvi P, Räsänen P, Malmivaara A, Aronen P, Sintonen H. Economic evaluation of drug-eluting stents: a systematic literature review and model-based cost-utility analysis. Int J Technol Assess Health Care 2007;23:473-9.
Eunethta. Core HTA on drug eluting stents. Finland 2008.
Bischof M, Briel M, Bucher HC, Nordmann A. Cost-effectiveness of drug-eluting stents in a US Medicare setting:a cost-utility analysis with 3-year clinical follow-up data. Value Health 2009;12:649-56.
Ferreira E, Araújo DV, Azevedo VM, Rodrigues CV, Ferreira A Jr, Junqueira Cde L, et al. Analysis of the cost-effectiveness of drug-eluting and bare-metal stents in coronary disease. Arq Bras Cardiol 2010;94:286-92, 306-12.
Schafer PE, Sacrinty MT, Cohen DJ, Kutcher MA, Gandhi SK, Santos RM, et al. Cost-effectiveness of drug-eluting stents versus bare metal stents in clinical practice. Circ Cardiovasc Qual Outcomes 2011;4:408-15.
Kutluer S. Cost effectiveness analysis of drug eluting stents and bare metal stents in the treatment of coronary artery disease. J of Soc Secur 2015;5:190-233.
Jamgyrchiev S, Fetcer DV, Pershukov IV, Özgül S, Batyraliev T. Clinical Impact of Drug-Eluting Coronary Stents. Turk J Inv Cardio 2016;10.